Optimal region of the putamen for image-guided convection-enhanced delivery of therapeutics in human and non-human primates - PubMed (original) (raw)
Optimal region of the putamen for image-guided convection-enhanced delivery of therapeutics in human and non-human primates
Dali Yin et al. Neuroimage. 2011 Jan.
Abstract
Optimal results in the direct brain delivery of brain therapeutics such as growth factors or viral vector into primate brain depend on reproducible distribution throughout the target region. In the present study, we retrospectively analyzed MRI of 25 convection-enhanced delivery (CED) infusions with MRI contrast into the putamen of non-human primates (NHP). Infused volume (V(i)) was compared to total volume of distribution (V(d)) versus V(d) within the target putamen. Excellent distribution of contrast agent within the putamen was obtained in eight cases that were used to define an optimal target volume or "green" zone. Partial or poor distribution with leakage into adjacent anatomical structures was noted in 17 cases, defining "blue" and "red" zones, respectively. Quantitative containment (99±1%) of infused gadoteridol within the putamen was obtained when the cannula was placed in the green zone, 87±3% in the blue zone and 49±0.05% in the red zone. These results were used to determine a set of 3D stereotactic coordinates that define an optimal site for putaminal infusions in NHP and human putamen. We conclude that cannula placement and definition of optimal (green zone) stereotactic coordinates have important implications in ensuring effective delivery of therapeutics into the putamen utilizing routine stereotactic MRI localization procedures and should be considered when local therapies such as gene transfer or protein administration are being translated into clinical therapy.
Keywords: MRI; Parkinson’s disease; cannula placement; convection-enhanced delivery; non-human primate.
Copyright © 2009 Elsevier Inc. All rights reserved.
Figures
Figure 1
Correlation of spatial coordinates and length of backflow with distribution of MRI tracer in the putamen
Figure 2. Stepped cannula placement in the putamen
(A) Schematic shows both step and tip portion of the cannula placement in green, blue and red zone for each case are shown. (B) Distribution is plotted as Vd in putamen vs. total Vd for each zone is shown (p<0.01). (C) Representative MR images showing distribution of Gadoteridol in the putamen for green, blue and red zones. Cannula placement and initial infusion are shown in panels C, D and E for each zone. Panels F, G and H show distribution of Gadoteridol in the brain after infusion into respective RGB zones. Note slight leakage into white matter tracts in G (blue) but pronounced leakage in H (red). Infusion into green zone (F) resulted in tracer distribution in putamen only.
Figure 3
RGB zones for step outlined in the putamen of NHP (A) and predicted for human putamen (B) based on the RGB parameters obtained in the NHP and compared on the same scale
Figure 4. 3D reconstruction of green zone and representative volumes of “green zone” in NHP (A and C) and human putamen (B and D)
Area of green zone was defined from MR images as a volume at least 3 mm ventral to the CC, at least 6 mm away from the AC (3 mm from cannula tip to AC plus 3 mm of tip length) vertically, greater than 2.75 mm from EC laterally, and more than 3 mm from IC medially.
Figure 5
Representative MR images showing distribution of Gadoteridol in the putamen and leakage into white matter tract at small and large infusion volume of MRI tracer
Similar articles
- Cannula placement for effective convection-enhanced delivery in the nonhuman primate thalamus and brainstem: implications for clinical delivery of therapeutics.
Yin D, Richardson RM, Fiandaca MS, Bringas J, Forsayeth J, Berger MS, Bankiewicz KS. Yin D, et al. J Neurosurg. 2010 Aug;113(2):240-8. doi: 10.3171/2010.2.JNS091744. J Neurosurg. 2010. PMID: 20367078 - Image-guided convection-enhanced delivery of GDNF protein into monkey putamen.
Gimenez F, Krauze MT, Valles F, Hadaczek P, Bringas J, Sharma N, Forsayeth J, Bankiewicz KS. Gimenez F, et al. Neuroimage. 2011 Jan;54 Suppl 1:S189-95. doi: 10.1016/j.neuroimage.2010.01.023. Epub 2010 Jan 18. Neuroimage. 2011. PMID: 20080195 - Pathways of infusate loss during convection-enhanced delivery into the putamen nucleus.
Brady ML, Raghavan R, Alexander A, Kubota K, Sillay K, Emborg ME. Brady ML, et al. Stereotact Funct Neurosurg. 2013;91(2):69-78. doi: 10.1159/000342492. Epub 2013 Jan 22. Stereotact Funct Neurosurg. 2013. PMID: 23344643 Free PMC article. - Distribution and chemical forms of gadolinium in the brain: a review.
Kanda T, Nakai Y, Hagiwara A, Oba H, Toyoda K, Furui S. Kanda T, et al. Br J Radiol. 2017 Nov;90(1079):20170115. doi: 10.1259/bjr.20170115. Epub 2017 Sep 28. Br J Radiol. 2017. PMID: 28749164 Free PMC article. Review. - Image-guided convection-enhanced delivery platform in the treatment of neurological diseases.
Fiandaca MS, Forsayeth JR, Dickinson PJ, Bankiewicz KS. Fiandaca MS, et al. Neurotherapeutics. 2008 Jan;5(1):123-7. doi: 10.1016/j.nurt.2007.10.064. Neurotherapeutics. 2008. PMID: 18164491 Free PMC article. Review.
Cited by
- Rapid inverse planning for pressure-driven drug infusions in the brain.
Rosenbluth KH, Martin AJ, Mittermeyer S, Eschermann J, Dickinson PJ, Bankiewicz KS. Rosenbluth KH, et al. PLoS One. 2013;8(2):e56397. doi: 10.1371/journal.pone.0056397. Epub 2013 Feb 15. PLoS One. 2013. PMID: 23457563 Free PMC article. - Gene Therapy for Neurodegenerative Diseases.
Sudhakar V, Richardson RM. Sudhakar V, et al. Neurotherapeutics. 2019 Jan;16(1):166-175. doi: 10.1007/s13311-018-00694-0. Neurotherapeutics. 2019. PMID: 30542906 Free PMC article. Review. - Glial-derived neurotrophic factor gene transfer for Parkinson's disease: anterograde distribution of AAV2 vectors in the primate brain.
Kells AP, Forsayeth J, Bankiewicz KS. Kells AP, et al. Neurobiol Dis. 2012 Nov;48(2):228-35. doi: 10.1016/j.nbd.2011.10.004. Epub 2011 Oct 14. Neurobiol Dis. 2012. PMID: 22019719 Free PMC article. Review. - Trial of magnetic resonance-guided putaminal gene therapy for advanced Parkinson's disease.
Heiss JD, Lungu C, Hammoud DA, Herscovitch P, Ehrlich DJ, Argersinger DP, Sinharay S, Scott G, Wu T, Federoff HJ, Zaghloul KA, Hallett M, Lonser RR, Bankiewicz KS. Heiss JD, et al. Mov Disord. 2019 Jul;34(7):1073-1078. doi: 10.1002/mds.27724. Epub 2019 May 30. Mov Disord. 2019. PMID: 31145831 Free PMC article. - Targeting the IL4 receptor with MDNA55 in patients with recurrent glioblastoma: Results of a phase IIb trial.
Sampson JH, Singh Achrol A, Aghi MK, Bankiewicz K, Bexon M, Brem S, Brenner A, Chandhasin C, Chowdhary S, Coello M, Ellingson BM, Floyd JR, Han S, Kesari S, Mardor Y, Merchant F, Merchant N, Randazzo D, Vogelbaum M, Vrionis F, Wembacher-Schroeder E, Zabek M, Butowski N. Sampson JH, et al. Neuro Oncol. 2023 Jun 2;25(6):1085-1097. doi: 10.1093/neuonc/noac285. Neuro Oncol. 2023. PMID: 36640127 Free PMC article.
References
- Aminoff MJ. Parkinson’s disease. Neurol Clin. 2001;19:119–128. vi. - PubMed
- Bankiewicz KS, Eberling JL, Kohutnicka M, Jagust W, Pivirotto P, Bringas J, Cunningham J, Budinger TF, Harvey-White J. Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neurol. 2000;164:2–14. - PubMed
- Carson BS, Sr, Wu Q, Tyler B, Sukay L, Raychaudhuri R, DiMeco F, Clatterbuck RE, Olivi A, Guarnieri M. New approach to tumor therapy for inoperable areas of the brain: chronic intraparenchymal drug delivery. J Neurooncol. 2002;60:151–158. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P01 CA118816-03/CA/NCI NIH HHS/United States
- P01 CA118816/CA/NCI NIH HHS/United States
- 1 P01 CA118816-01A2/CA/NCI NIH HHS/United States
- U54 NS045309/NS/NINDS NIH HHS/United States
- R01 NS056107/NS/NINDS NIH HHS/United States
- U54 NS045309-010002/NS/NINDS NIH HHS/United States
- R01 NS056107-03/NS/NINDS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources